Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 103M | 87M | 65M | 46M | 24M |
| Gross Profit | 93M | 79M | 57M | 39M | 22M |
| Operating Income | 9M | -7M | -4M | -13M | -7M |
| EBITDA | 12M | -2M | -289K | -12M | -7M |
| Net Income | -38M | -10M | -4M | -8M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$22.02
+3.77% today
1Y Change
-20.85%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sanara MedTech Inc. (SMTI) is a Healthcare stock with a market cap of $180.00M and listed on NASDAQ. The stock last traded around $22.02 and down 20.8% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +19.0%, EPS growth of -282.5%, a dividend yield of 0.0%. What stands out right now is revenue +19.0%, EPS -282.5%, free cash flow +953.9% with operating margin 8.9% and ROIC 16.7%. Valuation is more restrained than many high-expectation growth names at price/sales 1.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SMTI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SMTI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SMTI Max Drawdown
-54.29%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SMTI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$24.1M
-47.3% YoY
FY Net Income
-$7.9M
+0.2% YoY
Free Cash Flow
-$5.6M
+11.7% YoY
Revenue Growth
+19.0%
EPS Growth
-282.5%
Gross Margin
90.1%
Net Margin
-36.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 103M | 87M | 65M | 46M | 24M |
| Gross Profit | 93M | 79M | 57M | 39M | 22M |
| Operating Income | 9M | -7M | -4M | -13M | -7M |
| EBITDA | 12M | -2M | -289K | -12M | -7M |
| Net Income | -38M | -10M | -4M | -8M | -8M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 17M | 16M | 5M | 9M | 19M |
| Total Assets | 73M | 88M | 74M | 61M | 36M |
| Total Liabilities | 67M | 49M | 29M | 19M | 6M |
| Shareholder Equity | 6M | 39M | 45M | 42M | 31M |
| Total Debt | 48M | 32M | 12M | 819K | 425K |
| Net Debt | 32M | 16M | 7M | -8M | -18M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
5M
+13.3% YoY
Capital Expenditures
750K
-0.5% YoY
Free Cash Flow
6M
+11.7% YoY
Key ratios
Gross Margin
90.1%
Operating Margin
8.9%
Net Margin
-36.4%
ROE
-178.6%
Debt / Equity
8.13x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.